LifeMD Shares Undervalued: Analyst Initiates With Outperform Rating
Portfolio Pulse from Vandana Singh
Cantor Fitzgerald initiated coverage on LifeMD Inc (NASDAQ:LFMD) with an Overweight rating and a price target of $7, almost double the current price. The analyst sees LifeMD as an undervalued growth story in the virtual primary-care sector, expecting the company's topline to grow in the 20-30% CAGR range over the next 3-5 years. LifeMD's weight-management virtual clinic is seen as a key growth driver, with potential to tap into the $100-200B weight-loss medication market.
July 21, 2023 | 7:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
LifeMD's stock is expected to rise following Cantor Fitzgerald's Overweight rating and $7 price target. The company's growth potential in the virtual primary-care sector and the weight-loss medication market is seen as a key driver.
The Overweight rating and high price target set by Cantor Fitzgerald indicate a positive outlook for LifeMD's stock. The company's potential growth in the virtual primary-care sector and the weight-loss medication market, as well as its expected topline growth, are likely to attract investors and drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100